Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination

Pediatric Transplantation

Volumn 14, Issue 7, 2010, Pages 896-902

  Gupta, Sushil ^a   Fricker, Frederick J ^a   González Peralta, Regino P ^a   Slayton, William B ^a   Schuler, Pamela M ^a   Dharnidharka, Vikas R ^a  

^a University of Florida   (United States)

Author keywords

children; Epstein Barr virus; outcome; PTLD; rituximab; solid organ; transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; INTERFERON; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LOW DRUG DOSE; LUNG GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; ORGAN TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78349235420     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01370.x     Document Type: Article

References (40)

1. Dharnidharka VR, Araya CE,. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009: 24: 731-736.
2. Swerdlow SH,. Classification of the posttransplant lymphoproliferative disorders: From the past to the present. Semin Diagn Pathol 1997: 14: 2-7.
3. Swinnen LJ, Leblanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008: 86: 215-222.
4. Mcdonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008: 8: 984-989.
5. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006: 107: 3053-3057.
6. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005: 5: 2901-2906.
7. Shapiro RS, Chauvenet A, Mcguire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 1988: 318: 1334.
8. Svoboda J, Kotloff R, Tsai DE,. Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab. Transpl Int 2006: 19: 259-269.
9. Webber SA, Harmon WE, Faro A,. Anti-CD20 monoclonal antibody (rituximab) for refractory PTLD after pediatric solid organ transplantation: Multicenter experience from a registry and from a prospective clinical trial. Blood 2004: 104: 213a.
10. Cohen JI,. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991: 70: 137-160.
11. Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA,. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994: 97: 14-24.
12. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI,. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995: 86: 3333-3340.
13. Gross TG, Hinrichs SH, Winner J, et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy. Ann Oncol 1998: 9: 339-340.
14. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005: 23: 6481-6488.
15. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S,. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007: 92: 273-274.
16. Dharnidharka VR,. Epidemiology of PTLD. In:, Dharnidharka VR, Green M, Webber SA, eds. Post-Transplant Lymphoproliferative Disorders. Berlin: Springer-Verlag, 2009: pp. 17-28.
17. Hebert D, Sullivan EK,. Malignancy and post transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998: 1: 107.
18. Allen UD, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: A case-control study. Pediatr Transplant 2005: 9: 450-455.
19. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997: 131: 309-313.
20. Cohen AH, Sweet SC, Mendeloff E, et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000: 1 (4 Pt 1): 1252-1255.
21. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996: 62: 370-375.
22. Fernandez MC, Bes D, De Davila M, et al. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: Characteristics and outcome. Pediatr Transplant 2009: 13: 307-310.
23. Younes BS, Mcdiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000: 70: 94-99.
24. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 2006: 367: 233-239.
25. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991: 324: 1451-1456.
26. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010: 28: 1038-1046.
27. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004: 78: 1676-1682.
28. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC,. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998: 66: 1770-1779.
29. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lymphoproliferative disease in children: Correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001: 23: 14-18.
30. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001: 71: 1076-1088.
31. Gallego S, Llort A, Gros L, et al. Post-transplant lymphoproliferative disorders (PTLD) in children: The role of chemotherapy in the era of rituximab. Pediatr Transplant 2010: 14: 61-66.
32. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS,. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9 (10 Pt 2): 3945S-3952S.
33. Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007: 83: 912-918.
34. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: The role of single-agent rituximab. Transplantation 2007: 84: 1708-1712.
35. Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009: 9: 2331-2337.
36. Kerkar N, Morotti RA, Madan RP, et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant 2010: 14: 504-511.
37. Henry DD, Hunger SP, Braylan RC, Dharnidharka VR,. Low viral load post-transplant lymphoproliferative disease localized within the tongue. Transpl Infect Dis 2008: 10: 426-430.
38. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA,. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995: 80: 593-601.
39. Wagner HJ, Bein G, Bitsch A, Kirchner H,. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol 1992: 30: 2826-2829.
40. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD,. Multiple Epstein-Barr virus infections in healthy individuals. J Virol 2003: 77: 6546-6550.